- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04976205
AI Algorithms to Automate the TMI by VMAT Optimization Using WB-CT/MRI and Synthetic WB-CT - The AuToMI Project (AuToMI)
Artificial Intelligence Algorithms to Automate the Total Marrow (Lymph-node) Irradiation by VMAT Optimization Using WB-CT/MRI and Synthetic WB-CT - The AuToMI Project
Total Body Irradiation (TBI) was shown to help in providing immunosuppression that facilitates the donor transplant acceptance. Randomized trials demonstrated that conditioning regimens to bone marrow transplantation (BMT) including TBI have produced better survival rates than chemo-only regimens. The TBI target is represented by the whole BM, and eventually the whole lymphatic system, liver, spleen. The increased life expectancy revealed the occurrence of important toxicities because of full doses received by organs at risk (OARs) and this limited the use of TBI. Many groups have explored the possibility of sophisticated techniques for reducing the dose to healthy tissues while increasing the dose to the BM. These newer approaches aim to generate total marrow (lymph-node) irradiation (TMI/TMLI), sparing as much as possible non-skeletal and non-lymphoid structures.
Actually, the time required to optimize a TMI/TMLI plan is 10 days. Therefore, the simulation Computed Tomography (CT) is performed many days before the BMT. Furthermore, the lymph-nodes are defined only on CT images.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Total Body Irradiation (TBI) was shown to help in providing immunosuppression that facilitates the donor transplant acceptance. Moreover, TBI plays a role in the annihilation of malignant cells, and may also deplete normal hematopoietic stem cells, thus helping the donor marrow cells to repopulate the bone marrow (BM). Randomized trials demonstrated that conditioning regimens to BMT including TBI have produced better survival rates than chemo-only regimens.
The TBI target is represented by the whole BM, and eventually the whole lymphatic system, liver, spleen. Usually, a very simple geometry is adopted, with patient positioned on a dedicated couch at 3-4 meters away from the linear accelerator to fully cover the target with a single beam, avoiding field junctions.
The increased life expectancy revealed the occurrence of important toxicities because of full doses received by organs at risk (OARs) and this limited the use of TBI as stated by the 2018 ILGROG guidelines. Many groups have, therefore, explored the possibility of sophisticated techniques for reducing the dose to healthy tissues while increasing the dose to the BM. These newer approaches aim to generate total marrow (lymph-node) irradiation (TMI/TMLI), sparing as much as possible non-skeletal and non-lymphoid structures.
Preliminary clinical data on phase I/II trials support the use of TMI/TMLI as part of conditioning for BMT for relapsed-refractory acute leukemia patients and multiple myeloma. However, TMI/TMLI adoption is still very limited to few skilled hospitals due to the extreme difficulty in the planning that needs many days.
The evaluation of TMI/TMLI with Volumetric Modulated Arc Therapy (VMAT) was started in our institute in 2009 and we treated around 90 patients in 10 years.
VMAT-TMI/TMLI requires multiple arcs from isocenters with different positions to fully include the patient length. Therefore, many field junctions between arcs with different isocenters should be managed. Furthermore, the CT length does not allow to acquire the patient in a single CT scan. Two CT series must be acquired and co-registered.
Actually, the time required to optimize a TMI/TMLI plan is 10 days. Therefore, the simulation Computed Tomography (CT) is performed many days before the BMT. Furthermore, the lymph-nodes are defined only on CT images.
Deep learning (DL) artificial intelligence (AI) algorithms in medical imaging and RT are rapidly expanding. DL focused on lesion detection and classification by features extraction. Image segmentations using fully convolutional network (FCN), holistically nested network (HNN) or other customized network architectures were implemented in many regions.
Over the past decades, the use of magnetic resonance imaging (MRI) to support RT has increased. MRI provides excellent soft-tissue imaging that could improve the target definition. The lymph-nodes contouring, based on MRI, will result in smaller target, enabling a better sparing of healthy tissues. Moreover, MRI significantly reduces inter/intra-observer contouring variability. At this aim, new generation MRI consoles with larger bore size, flat tabletops and dedicated imaging protocols with reduced image distortion to <1 mm were developed. Moreover, newly developed gradient-echo 3D sequences, and dedicated coils, can be used for producing a whole body WB-MRI acquisition in a few minutes. Furthermore, synthetic CT from MRI was proposed and implemented in some regions (i.e. brain and prostate) to substitute the CT for providing electron density information for dose planning calculation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- IRCCS Humanitas Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written, signed informed consent
- Adult patients aged ≥18 years
- Diagnosis of Hematological disease
- Eligibility for allogeneic stem cell transplantation as center guidelines
- TMI/TLI as part of the conditioning regimen
Exclusion Criteria:
- Conditioning regimen including only chemotherapeutic agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TMI/TMLI
The standard planning optimization for TMI/TMLI preview a two-free-breathing-CT scan without contrast will be performed for simulation at day -15(-10) to the BMT. The same day a WB-MRI will be acquired for lymph-nodes delineation. WB-MRI scans will be performed using a 1.5T MR scanner. The two CT will be co-registered to the WB-MRI. CTV will be manually defined as the bones excluding mandible and hands (CTVBones), the spleen (CTVSpleen), and lymph nodes (CTVLN) using both MRI and CT images. The day -3 (4) to the BMT, further two-CT series will be acquired and co-registered to the first CTs for dose verification. Pre-treatment quality assurance (QA) will be performed the day before the treatment using the standard internal procedure. The treatment will be performed the day before the BMT. |
To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT.
A verification WB-CT will be performed 3/4 days before the delivery.
Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of Lymph nodes target volume thanks to WB-MRI
Time Frame: 3 years
|
The PTV_LN volumes generated on the Simulation WB-MRI and on the Simulation WB-CT will be compared.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Doses calcuated on CT performed at day -3 (4) to the BMT
Time Frame: 3 years
|
To evaluate the dosimetric changes that occurs in the days between the simulation and the delivery. The RT plan is defined on a simulation CT perfomed at -15 days. A second CT is performed at day -3 (4) to the BMT. The RT plan is recalculated on the second CT. The PTV volume receiving 95% of doses will be recorded. |
3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2928
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Disease
-
University of ChicagoTerminated
-
Charite University, Berlin, GermanyUnknownHematological DiseaseGermany
-
Chroma TherapeuticsCompletedLymphoid Malignancies | Hematological DiseaseFrance, Belgium, Netherlands
-
Institute of Hematology & Blood Diseases HospitalRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematological DiseaseChina
-
Assiut UniversityNot yet recruitingAngiodysplasia | Hematological Disease
-
Christopher ReillyBroad Institute of MIT and HarvardRecruitingGenetic Predisposition to Disease | Myeloid Malignancy | Myeloid Hematological MalignanciesUnited States
-
Spectrum Health HospitalsMillennium Pharmaceuticals, Inc.CompletedHematological MalignancyUnited States
-
Ruijin HospitalActive, not recruitingHematologic Disease | Precise Design of Cell Therapy for Relapsed and Refractory Hematological TumorsChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaCompletedCytomegalovirus Infections | Hematological DiseaseChina
-
University Hospital HeidelbergUniversity of Cologne; University Hospital Freiburg; University Hospital DresdenTerminated
Clinical Trials on Total Marrow (Lymph-node) Irradiation
-
Samsung Medical CenterRecruitingBreast Cancer Stage IIIKorea, Republic of
-
Fujian Medical UniversityUnknownThyroid Carcinoma | Endoscopic Surgery | Robot SurgeryChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States, Canada, Australia, Ireland
-
Ruijin HospitalRecruiting
-
Institute of Hematology and Blood Transfusion,...Proton Therapy Center Czech s.r.o.RecruitingAcute Myeloid Leukemia (AML) | Proton Therapy | MDS and AML Prior to Allogeneic SCT | Myelodysplastic Neoplasm | Myelodysplastic Syndrome (MDS)/AMLCzechia
-
Hospital Universitario Dr. Jose E. GonzalezCompletedAcute Lymphoblastic LeukemiaMexico
-
Radboud University Medical CenterUniversity Medical Center Groningen; Maastricht University Medical Center; UMC... and other collaboratorsRecruitingOropharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Hypopharynx Squamous Cell CarcinomaNetherlands
-
Ottawa Hospital Research InstituteRecruiting
-
Karolinska InstitutetWithdrawn
-
Mayo ClinicNational Institute of Allergy and Infectious Diseases (NIAID)CompletedTransplantation, Kidney | Kidney Transplant Recipients | Living DonorsUnited States